Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Fineline Cube Apr 21, 2026
Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development

Fineline Cube Apr 21, 2026
Company Drug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

Fineline Cube Apr 21, 2026
Policy / Regulatory

China Meheco Keyi Pharma’s Ganciclovir Loses VBP Bid After Inspection Failure

Fineline Cube Jan 10, 2023

The national drug alliance procurement office has released a notification indicating that China Meheco Keyi...

Policy / Regulatory

NMPA Releases 63rd Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has released the 63rd batch of reference drugs for...

Company Drug

Cosunter’s COVID-19 Drug GST-HG171 Shows Superior Efficacy in Trial

Fineline Cube Jan 10, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced positive results from an investigator-initiated...

Company Drug

Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China

Fineline Cube Jan 10, 2023

The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan...

Policy / Regulatory

NMPA Approves Expanded Production for COVID-19 Symptom Treatments

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has approved filings from multiple companies to expand manufacturing...

Company Drug

Roche’s Glofitamab and Dizal’s Sunvozertinib Enter Priority Review

Fineline Cube Jan 10, 2023

The Center for Drug Evaluation (CDE) website indicates that Swiss giant Roche’s (SWX: ROG) glofitamab...

Company Deals

Yinjia Biosciences Raises RMB 100 Million in Series A Financing Round

Fineline Cube Jan 10, 2023

Yinjia Biosciences, a Shanghai-based developer of protein reagents and diagnostic products, has reportedly raised close...

Policy / Regulatory

China Optimizes Medical Insurance Policies for COVID-19 Treatment

Fineline Cube Jan 10, 2023

The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center...

Company Deals

China Resources Biopharmaceutical Secures RMB 600 Million in Series B Funding

Fineline Cube Jan 10, 2023

China Resources Biopharmaceutical Co., Ltd has announced the completion of a Series B financing round,...

Company Drug

Adagene’s ADG126 Shows Promise in Combination with Anti-PD-1 Therapy

Fineline Cube Jan 10, 2023

China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...

Company

Pfizer CEO Denies Licensing Paxlovid to Chinese Generics Firms

Fineline Cube Jan 10, 2023

Pfizer Inc. (NYSE: PFE) CEO Albert Bourla, speaking on the sidelines of the JPMorgan Healthcare...

Company

Legend Biotech Receives Nasdaq Notice Regarding Listing Compliance

Fineline Cube Jan 10, 2023

Legend Biotech Corporation (NASDAQ: LEGN) announced on January 6, 2023, that it received a notice...

Company Drug

Jiangxi Jemincare’s JMKX003142 Gets FDA Nod for Clinical Study

Fineline Cube Jan 9, 2023

China-based Jiangxi Jemincare Group has announced receiving approval from the US Food and Drug Administration...

Company Drug Policy / Regulatory

Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute

Fineline Cube Jan 9, 2023

The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy...

Policy / Regulatory

China Strengthens COVID-19 Prevention and Control in Rural Areas

Fineline Cube Jan 9, 2023

China has intensified its COVID-19 prevention and control measures in rural areas, with the State...

Company Drug

Eli Lilly’s Donanemab Set to Gain Breakthrough Therapy Designation in China

Fineline Cube Jan 9, 2023

The Center for Drug Evaluation (CDE) website indicates that US-based Eli Lilly’s (NYSE: LLY) injectable...

Company Deals

Changzhou Sifary Medtech Secures Series B Funding for Global Expansion

Fineline Cube Jan 9, 2023

Changzhou Sifary Medical Technology Co., Ltd, a China-based platform for the globalization of oral medical...

Company Drug

Suzhou Thery’s Generic Nilotinib Approved by China’s NMPA

Fineline Cube Jan 9, 2023

China-based Suzhou Thery Pharmaceutical Inc. has announced that the National Medical Products Administration (NMPA) has...

Company Drug

Zhifei Biological Products’ BCG Vaccine Filing Accepted by China’s NMPA

Fineline Cube Jan 9, 2023

China-based Chongqing Zhifei Biological Products Co., Ltd (SHE: 300122) has announced that its clinical trial...

Company Drug

Yantai Dongcheng Pharma Gets FDA Go-Ahead for 177Lu-LNC1004 Clinical Trial

Fineline Cube Jan 9, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Posts pagination

1 … 564 565 566 … 654

Recent updates

  • Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma
  • Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development
  • China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive
  • FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer
  • Boehringer Ingelheim Opens AI & Machine Learning Hub in London, Commits €150M to Accelerate Drug Discovery for High-Unmet-Need Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

Company Drug

Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development

Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Company Drug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.